Skip to content

Oral Pregabalin Effect to the Intravenous Morphine in Multiple Fracture Ribs

The Effect of Adding Pregabalin to the Analgesic Effect of Intravenous Morphine in Patients With Multiple Fracture Ribs

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03473093
Enrollment
80
Registered
2018-03-22
Start date
2018-03-31
Completion date
2019-04-30
Last updated
2018-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture; Rib, Multiple

Brief summary

Determine the effect of using oral pregabalin on the analgesic effects of IV infusion of morphine in patients with multiple fracture ribs.

Detailed description

Blunt chest trauma accounts for a significant proportion of debilitating and life-threatening injuries. Rib fractures are notoriously painful and can lead to prolonged hospitalization,contribute to the development of pneumonia and respiratory failure, and delay outpatient recovery significantly.Flail chest, along with chest wall deformity, the most severe of chest wall injuries, is associated with significant acute morbidity and mortality.Flail chest injury has been associated with a high mortality rates historically and up to 16 % more recently. In-patients with physiologic flail visibly apparent paradoxical chest wall motion leads to inefficient respiratory effort and compression of the lung and diminishes the negative intra thoracic pressure essential for the passive movement of air into the bronchial tree. Atelectasis leads to increased lung resistance and decreased compliance, making the work of breathing much more difficult. Loss of the ability to generate negative intra thoracic pressure with breathing also impairs venous return, a passive process dependent on the negative intra thoracic pressure generated with each breath. In patients without a visible flail segment, i.e., an anatomic or radiologic flail,the physiologic derangements can be similarly destructive.There is mounting evidence that a patient's perception of pain in the early post-injury period is associated with chronic pain development . A recent prospective study of rib fracture patients found that pain and disability at 8 weeks post injury could be predicted by the pain intensity within the first few days after injury . Interestingly, the number of fractures and the bilaterality of fractures were not predictive. Thus, pain management in the early post-injury setting is likely paramount to obtaining a more favorable recovery. Opioids, are traditional first-line therapy for acute rib fracture pain. But because of chronic misuse potential and central desensitization concerns, pain researchers and clinicians are increasingly recommending that opioids be used only in combination with other analgesic modalities such acetaminophen, nonsteroidal anti-inflammatory medication(NSAID), the anticonvulsants gabapentin and pregabalin,and the topical lidocaine patch

Interventions

DRUGPregabalin 150mg

One group will receive oral pregabalin with morphine infusion

DRUGMorphine

One group will receive morphine infusion 20 microgram/kg/h

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients above 18 years old * ASA \[1\] and ASA \[2\] * mentally competent and able to give consent for enrollment in the study

Exclusion criteria

* Patient coma scale less than 10 * Impaired kidney functions * Chronic pain syndromes and patients with chronic opioid use

Design outcomes

Primary

MeasureTime frameDescription
decrease painone weekmeasured by visual analogue score ranged from 0 to 10 with higher numbers are worse than lower numbers

Secondary

MeasureTime frameDescription
I.C.U stay timeone weekdecrease time

Contacts

Primary Contactkhaled mohamad morsy, PhD
khaledmorsy@gmail.com01090477966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026